福泰製藥公司
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionZions Bancorporation
Latest Disclosed Ownership463 shares
Latest Disclosed Value $ 89,000
Zions Bancorporation reports 5.47% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On November 2, 2018 - Zions Bancorporation filed a 13F-HR form disclosing ownership of 463 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $89,239 USD as of September 30, 2018. The entity filed a previous 13F-HR on August 9, 2018 disclosing 439 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 5.47% during the quarter. The current value of the position is $206,882 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2018-11-02 2018-09-30 13F Vertex Pharma Com 92532F100 463 24 5.47 89 18.67 0.0212
2018-08-09 2018-06-30 13F Vertex Pharma Com 92532F100 439 439 75 0.0515
2018-05-03 2018-03-31 13F Vertex Pharma Com 92532F100 0 -446 -100.00 0 -100.00
2018-02-14 2017-12-31 13F Vertex Pharma Com 92532F100 446 22 5.19 67 4.69 0.0115
2017-11-14 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 424 367 643.86 64 814.29 0.0092
2017-08-14 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 57 -69 -54.76 7 -53.33 0.0012
2017-05-17 2017-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 126 -148 -54.01 15 -25.00 0.0028
2017-05-15 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 274 20
2017-02-14 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 274 42 18.10 20 17.65 0.0035
2016-11-15 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 232 40 20.83 17 0.00 0.0032
2016-08-15 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 192 12 6.67 17 6.25 0.0030
2016-05-16 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 180 34 23.29 16 23.08 0.0029
2016-02-16 2015-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 146 -22 -13.10 13 -35.00 0.0023
2016-02-16 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 146 13
2015-11-16 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 168 168 0.00 20 0.0037
2015-08-13 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -163 -100.00 0 -100.00
2015-05-13 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 163 163 19 0.0033
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.